Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nitric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 9/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.53 |
| ▸ | MEN1 | O00255 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 4/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1186622 | 0.87 | NPC1 (0.61) | NPC1MAPTALDH1A1MEN1KMT2A | |
| Nitric Acid SCHEMBL2852035 | 0.84 | PEPD (0.52) | MAPTALDH1A1MEN1KMT2ALMNA | |
| Bicarbonate SCHEMBL3281891 | 0.83 | NPC1 (0.64) | NPC1MAPTALDH1A1MEN1KMT2A | |
| Nitric Acid SCHEMBL3860512 | 0.82 | KMT2A (0.59) | NPC1MAPTALDH1A1MEN1KMT2A | |
| Nitric Acid SCHEMBL4613840 | 0.82 | ALDH1A1 (0.53) | MAPTALDH1A1MEN1KMT2ALMNA | |
| Nitric Acid SCHEMBL9982936 | 0.82 | LMNA (0.49) | NPC1MAPTALDH1A1MEN1KMT2A | |
| Nitric Acid SCHEMBL1833737 | 0.82 | MEN1 (0.46) | NPC1MAPTALDH1A1MEN1KMT2A | |
| Nitric Acid SCHEMBL1184061 | 0.82 | CA1 (0.44) | MEN1KMT2ACA12CA1CA2 | |
| Nitric Acid SCHEMBL4463275 | 0.82 | IDO1 (0.42) | MAPTALDH1A1MEN1KMT2ALMNA | |
| Phenylguanidine SCHEMBL2847797 | 0.81 | MAPT (0.50) | NPC1MAPTALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263901-A1 | Process of Preparation of Proguanil | USV LTD. (IN) | 2011-10-27 | — | — | US | disclosed |
| EP-2150528-A2 | PROCESS FOR PREPARATION OF PROGUANIL HYDROCHLORIDE | USV Limited (IN) | 2010-02-10 | — | — | EP | disclosed |
| WO-2009113092-A2 | PROCESS FOR PREPARATION OF PROGUANIL HYDROCHLORIDE | USV LIMITED (IN) | 2009-09-17 | — | — | WO | disclosed |
| CN-100355751-C | 2-substd. 4-heteroaryl-pyrimidines and their use in treatment of proliferative disorders | CYCLACEL LTD (GB) | 2007-12-19 | — | — | CN | disclosed |
| US-6699854-B2 | 2-SUBSTITUTED 4-HETEROARYL- PYRIMIDINES, INHIBITORS OF CYCLIN-DEPENDENT KINASES (CDKS) | CYCLACEL LIMITED (GB) | 2004-03-02 | — | — | US | disclosed |
| US-20030149057-A1 | Anti-cancer compounds | CYCLACEL LIMITED (GB) | 2003-08-07 | — | — | US | disclosed |
| CN-1420884-A | 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative diseases | CYCLACEL LTD (GB) | 2003-05-28 | — | — | CN | disclosed |
| US-6531479-B2 | Anticancer agents, skin disorders | CYCLACEL LIMITED (GB) | 2003-03-11 | — | — | US | disclosed |
| EP-1274705-A1 | 2-SUBSTITUTED 4-HETEROARYL-PYRIMIDINES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS | Cyclacel Limited (GB) | 2003-01-15 | — | — | EP | disclosed |
| US-20020019404-A1 | Anti-cancer compounds | CYCLACEL LIMITED (GB) | 2002-02-14 | — | — | US | disclosed |
| WO-2001072745-A1 | 2-SUBSTITUTED 4-HETEROARYL-PYRIMIDINES AND THEIR USE IN THE TREATMETN OF PROLIFERATIVE DISORDERS | CYCLACEL LIMITED (GB) | 2001-10-04 | — | — | WO | disclosed |
| US-4587337-A | Process for the preparation of 2-amino-s-triazines | SKW TROSTBERG AKTIENGESELLSCHAFT (DE) | 1986-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019404-A1 | Anti-cancer compounds | CDK3, CDK2, CDK4 | NPC1 3873/4885MAPT 2289/4885ALDH1A1 3103/4885 |
| US-20030149057-A1 | Anti-cancer compounds | CDK3, CDK2, CDK4 | NPC1 3873/4885MAPT 2289/4885ALDH1A1 3103/4885 |
| US-20110263901-A1 | Process of Preparation of Proguanil | GCG, PREP, G6PD | NPC1 2777/4885MAPT 3758/4885ALDH1A1 2610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.